Tang Capital Management’s Vaxcyte PCVX Stock Holding History

Tang Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-275,000	Closed	-$12.7M	–	65
2025 Q4	$12.7M	Sell	275,000 -25,000	-8%	-$1.12M	0.63%	34
2025 Q3	$10.8M	Hold	300,000	–	–	0.42%	61
2025 Q2	$9.75M	Hold	300,000	–	–	0.49%	54
2025 Q1	$11.3M	Hold	300,000	–	–	0.63%	41
2024 Q4	$24.6M	Hold	300,000	–	–	1.62%	15
2024 Q3	$34.3M	Hold	300,000	–	–	2.45%	9
2024 Q2	$22.7M	Hold	300,000	–	–	2.31%	10
2024 Q1	$20.5M	Hold	300,000	–	–	2.13%	10
2023 Q4	$18.8M	Hold	300,000	–	–	1.74%	15
2023 Q3	$15.3M	Hold	300,000	–	–	2.16%	13
2023 Q2	$15M	Hold	300,000	–	–	2.21%	15
2023 Q1	$11.2M	Hold	300,000	–	–	1.68%	19
2022 Q4	$14.4M	Buy	+300,000	New	+$11.8M	2.09%	15

Other funds holding PCVX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tang Capital Management's PCVX Position: Q1 2026 in Review

Tang Capital Management sold out of Vaxcyte (PCVX) in Q1 2026, closing a stake of 275,000 shares — an estimated $12.7M sold.

Tang Capital Management first reported a position in PCVX in Q4 2022 and held it in 13 quarters. The position peaked at $34.3M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

Tang Capital Management reported no remaining Vaxcyte position as of Q1 2026 after selling out during the quarter.
Tang Capital Management sold 275,000 Vaxcyte shares in Q1 2026, an estimated $12.7M.
Tang Capital Management first reported a position in Vaxcyte in Q4 2022 and held it in 13 quarters.
Tang Capital Management's Vaxcyte position peaked at $34.3M in Q3 2024.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.